Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Tuberculosis

Free Subscription Articles published in Am J Respir Crit Care Med Retrieve available abstracts of 70 articles: HTML format

Single Articles

May 2024
1. DAVIES GR
   Reconsidering the Role of Isoniazid in Drug-resistant Tuberculosis.
   Am J Respir Crit Care Med. 2024 May 1. doi: 10.1164/rccm.202403-0628.
   PubMed    
   
   
   April 2024
2. MATHEMA B, Burzynski J
   One Half of the Pair: Prioritizing Tuberculosis Transmitters for Early Detection.
   Am J Respir Crit Care Med. 2024 Apr 30. doi: 10.1164/rccm.202404-0699.
   PubMed    
   
   
   
3. DRAIN PK
   Another Step Closer to Genomic-informed Therapeutic Dosing for Tuberculosis Drugs.
   Am J Respir Crit Care Med. 2024 Apr 22. doi: 10.1164/rccm.202403-0566.
   PubMed    
   
   
   
4. GAUSI K, Ignatius EH, De Jager V, Upton C, et al
   High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
   Am J Respir Crit Care Med. 2024 Apr 2. doi: 10.1164/rccm.202311-2004.
   PubMed     Abstract available
   
   
   March 2024
5. VERMA R, Silva KED, Rockwood N, Wasmann RE, et al
   A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
   Am J Respir Crit Care Med. 2024 Mar 5. doi: 10.1164/rccm.202309-1583.
   PubMed     Abstract available
   
   
   February 2024
6. TREVISI L, Brooks MB, Becerra MC, Calderon RI, et al
   Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
   Am J Respir Crit Care Med. 2024 Feb 28. doi: 10.1164/rccm.202307-1217.
   PubMed     Abstract available
   
   
   October 2023
7. ANIDI IU, Kirenga B, Fennelly KP
   Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
   Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1571.
   PubMed    
   
   
   
8. ROCHESTER CL, Alison JA, Carlin B, Holland AE, et al
   Reply to: Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
   Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1714.
   PubMed    
   
   
   July 2023
9. OTTEWILL C, Dolan L, Lopez Bailen E, Roycroft E, et al
   Immunosuppressed Pets as a Conduit for Zoonotic Tuberculosis.
   Am J Respir Crit Care Med. 2023 Jul 25. doi: 10.1164/rccm.202304-0734.
   PubMed    
   
   
   June 2023
10. PATANKAR S, Cruz AT, Douglas-Jones B, Garcia-Prats A, et al
    Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jun 5. doi: 10.1164/rccm.202304-0670.
    PubMed    
    
    
    
11. BRUST JCM
    "Weighting" the Evidence: How Much Bedaquiline Is Enough?
    Am J Respir Crit Care Med. 2023;207:1423-1424.
    PubMed    
    
    
    May 2023
12. MITNICK CD, Nunn AJ
    Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
    Am J Respir Crit Care Med. 2023;207:1269-1270.
    PubMed    
    
    
    
13. KURBATOVA EV, Phillips PPJ, Dorman SE, Sizemore EE, et al
    A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2023;207:1376-1382.
    PubMed     Abstract available
    
    
    April 2023
14. BORGES DE ALMEIDA CP, Mitnick CD
    Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202303-0601.
    PubMed    
    
    
    
15. MARTINEZ L, Zar HJ
    Reply to: Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202304-0629.
    PubMed    
    
    
    
16. MASEKELA R, Mandalakas AM
    Pediatric Post-TB Lung Disease: Ready for Prime Time?
    Am J Respir Crit Care Med. 2023;207:975-977.
    PubMed    
    
    
    February 2023
17. TREVISI L, Hernan MA, Mitnick CD, Khan U, et al
    Effectiveness of Bedaquiline Use Beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
    Am J Respir Crit Care Med. 2023 Feb 21. doi: 10.1164/rccm.202211-2125.
    PubMed     Abstract available
    
    
    
18. MARTINEZ L, Gray DM, Botha M, Nel M, et al
    The Long-Term Impact of Early-Life Tuberculosis Disease on Child Health: A Prospective Birth Cohort Study.
    Am J Respir Crit Care Med. 2023 Feb 6. doi: 10.1164/rccm.202208-1543.
    PubMed     Abstract available
    
    
    January 2023
19. STAGG HR, Thompson JA, Lipman MCI, Sloan DJ, et al
    Forgiveness Is the Attribute of the Strong: Nonadherence and Regimen Shortening in Drug-sensitive Tuberculosis.
    Am J Respir Crit Care Med. 2023;207:193-205.
    PubMed     Abstract available
    
    
    
20. VELASQUEZ GE, Nahid P
    Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-Susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jan 11. doi: 10.1164/rccm.202212-2262.
    PubMed    
    
    
    December 2022
21. DOOLEY KE, Hendricks B, Gupte N, Barnes G, et al
    Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results.
    Am J Respir Crit Care Med. 2022 Dec 1. doi: 10.1164/rccm.202208-1475.
    PubMed     Abstract available
    
    
    
22. 
    Erratum: Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022;206:1434.
    PubMed    
    
    
    October 2022
23. CHECKLEY W
    Tuberculosis, Wildfires, and Case-Crossover Studies: An Epidemiological Trifecta?
    Am J Respir Crit Care Med. 2022 Oct 31. doi: 10.1164/rccm.202210-1936.
    PubMed    
    
    
    September 2022
24. 
    Erratum: Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2022;206:800-801.
    PubMed    
    
    
    
25. LINDE LR, Readhead A, Barry PM, Balmes JR, et al
    Tuberculosis Diagnoses Following Wildfire Smoke Exposure in California.
    Am J Respir Crit Care Med. 2022 Sep 14. doi: 10.1164/rccm.202203-0457.
    PubMed     Abstract available
    
    
    June 2022
26. MARAIS BJ, Graham SM
    The Value of Chest Radiography in Tuberculosis Preventive Treatment (TPT) Screening in Children and Adolescents.
    Am J Respir Crit Care Med. 2022 Jun 2. doi: 10.1164/rccm.202205-1023.
    PubMed    
    
    
    May 2022
27. DOWDY DW
    Coughing is Not Required to Transmit Mycobacterium tuberculosis: Another Nail in the Coffin.
    Am J Respir Crit Care Med. 2022 May 25. doi: 10.1164/rccm.202204-0645.
    PubMed    
    
    
    
28. HUANG CC, Tan Q, Becerra MC, Calderon R, et al
    The Contribution of Chest Radiography to the Clinical Management of Children Exposed to Tuberculosis.
    Am J Respir Crit Care Med. 2022 May 24. doi: 10.1164/rccm.202202-0259.
    PubMed     Abstract available
    
    
    
29. DINKELE R, Gessner S, McKerry A, Leonard B, et al
    Aerosolization of Mycobacterium tuberculosis by Tidal Breathing.
    Am J Respir Crit Care Med. 2022 May 18. doi: 10.1164/rccm.202110-2378.
    PubMed     Abstract available
    
    
    
30. DE JAGER V, Gupte N, Nunes S, Barnes GL, et al
    Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.
    Am J Respir Crit Care Med. 2022;205:1228-1235.
    PubMed     Abstract available
    
    
    
31. ESMAIL A, Oelofse S, Lombard C, Perumal R, et al
    An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Am J Respir Crit Care Med. 2022;205:1214-1227.
    PubMed     Abstract available
    
    
    April 2022
32. SHAKU MT, Bishai WR
    Mycobacterium tuberculosis: A Pathogen That Can Hold its Breath a Long Time.
    Am J Respir Crit Care Med. 2022 Apr 20. doi: 10.1164/rccm.202203-0432.
    PubMed    
    
    
    
33. BUCSAN AN, Veatch A, Singh DK, Akter S, et al
    Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022 Apr 12. doi: 10.1164/rccm.202112-2747.
    PubMed     Abstract available
    
    
    
34. PITTET LF, Fritschi N, Tebruegge M, Dutta B, et al
    Bacillus Calmette-Guerin Skin Reaction Predicts Enhanced Mycobacteria-Specific T-Cell Responses in Infants: A Post Hoc Analysis of a Randomized Controlled Trial.
    Am J Respir Crit Care Med. 2022;205:830-841.
    PubMed     Abstract available
    
    
    March 2022
35. LANGE C, Barry Iii CE, Horsburgh CR Jr
    Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
    Am J Respir Crit Care Med. 2022 Mar 23. doi: 10.1164/rccm.202202-0393.
    PubMed    
    
    
    January 2022
36. SCHLUGER NW
    Of Mice and Men, Women, and Children: Using Animal Models to Inform Tuberculosis Clinical Trials of Novel Agents.
    Am J Respir Crit Care Med. 2022 Jan 31. doi: 10.1164/rccm.202112-2866.
    PubMed    
    
    
    
37. O'DONNELL M, Mathema B
    Expanding the Tuberculosis Cascade of Care to Treat Undiagnosed and Subclinical Tuberculosis in High-Burden Settings.
    Am J Respir Crit Care Med. 2022;205:149-151.
    PubMed    
    
    
    December 2021
38. KAUSHIK A, Ammerman NC, Tasneen R, Lachau-Durand S, et al
    Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy.
    Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541.
    PubMed     Abstract available
    
    
    
39. FENNELLY KP, Martinez L, Mandalakas AM
    Tuberculosis: First in Flight.
    Am J Respir Crit Care Med. 2021 Dec 14. doi: 10.1164/rccm.202111-2513.
    PubMed    
    
    
    
40. SHIMIZU T, Watanabe S, Murata A, Kasahara K, et al
    Bronchial Cast Hiding Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2021 Dec 3. doi: 10.1164/rccm.202105-1306.
    PubMed    
    
    
    
41. SCHLUGER NW
    Using Isoniazid More Safely and More Effectively: The Time Is Now.
    Am J Respir Crit Care Med. 2021;204:1248-1250.
    PubMed    
    
    
    November 2021
42. BUNYASI EW, Middelkoop K, Koch A, Hoosen Z, et al
    Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools.
    Am J Respir Crit Care Med. 2021 Nov 9. doi: 10.1164/rccm.202102-0405.
    PubMed     Abstract available
    
    
    
43. ADJOBIMEY M, Behr MA, Menzies D
    Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity.
    Am J Respir Crit Care Med. 2021;204:1013-1014.
    PubMed    
    
    
    October 2021
44. ATRE SR, Jagtap JD, Faqih MI, Dumbare YK, et al
    Tuberculosis Pathways to Care and Transmission of Multidrug-Resistance in India.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202012-4333.
    PubMed     Abstract available
    
    
    
45. NOURSADEGHI M, Gupta RK
    New Insights into the Limitations of Host-Transcriptional Biomarkers of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202109-2146.
    PubMed    
    
    
    September 2021
46. MULENGA H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, et al
    Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Sep 14. doi: 10.1164/rccm.202103-0548.
    PubMed     Abstract available
    
    
    
47. DARTOIS V, Dick T
    A Ginger Root or Plum Model for the Tuberculosis "Granuloma"?
    Am J Respir Crit Care Med. 2021;204:505-507.
    PubMed    
    
    
    August 2021
48. DAVIS JL, Checkley W
    Characterization of Air Pollution Exposures as Risk Factors for Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Aug 30. doi: 10.1164/rccm.202107-1795.
    PubMed    
    
    
    
49. GAUSI K, Ignatius EH, Sun X, Kim S, et al
    A Semi-Mechanistic Model of the Bactericidal Activity of High-Dose Isoniazid Against Multi-Drug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
    Am J Respir Crit Care Med. 2021 Aug 17. doi: 10.1164/rccm.202103-0534.
    PubMed     Abstract available
    
    
    
50. MITNICK CD, Furin JJ, Hewison C
    The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202106-1516.
    PubMed    
    
    
    
51. VERMA R, Patil S, Zhang N, Moreira FMF, et al
    A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202103-0564.
    PubMed     Abstract available
    
    
    
52. IMPERIAL MZ, Phillips PPJ, Nahid P, Savic RM, et al
    Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2021 Aug 4. doi: 10.1164/rccm.202101-0117.
    PubMed     Abstract available
    
    
    
53. BLOUNT RJ, Phan H, Trinh T, Dang H, et al
    Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children.
    Am J Respir Crit Care Med. 2021 Aug 3. doi: 10.1164/rccm.202101-0136.
    PubMed     Abstract available
    
    
    June 2021
54. ROELENS M, Battista Migliori G, Rozanova L, Estill J, et al
    Evidence-based Definition for Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Jun 9. doi: 10.1164/rccm.202009-3527.
    PubMed     Abstract available
    
    
    May 2021
55. WELLS G, Glasgow JN, Nargan K, Lumamba K, et al
    microCT Analysis of the Human Tuberculous Lung Reveals Remarkable Heterogeneity in 3D Granuloma Morphology.
    Am J Respir Crit Care Med. 2021 May 20. doi: 10.1164/rccm.202101-0032.
    PubMed     Abstract available
    
    
    April 2021
56. 
    Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2021;203:1045.
    PubMed    
    
    
    
57. HUDDART S, Savic RM, Cattamanchi A
    Is Glycemic Control the Secret to Tuberculosis Control?
    Am J Respir Crit Care Med. 2021 Apr 7. doi: 10.1164/rccm.202103-0703.
    PubMed    
    
    
    March 2021
58. BEHR MA, Kaufmann E, Duffin J, Edelstein PH, et al
    Latent Tuberculosis: Two Centuries of Confusion.
    Am J Respir Crit Care Med. 2021 Mar 24. doi: 10.1164/rccm.202011-4239.
    PubMed     Abstract available
    
    
    
59. LIU Q, You N, Pan H, Shen Y, et al
    Glycemic Trajectories After Tuberculosis Diagnosis and Treatment Outcomes of New Tuberculosis Patients: A Prospective Study in Eastern China.
    Am J Respir Crit Care Med. 2021 Mar 11. doi: 10.1164/rccm.202007-2634.
    PubMed     Abstract available
    
    
    
60. KENDALL EA, Shrestha S, Dowdy DW
    Reply to: Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202102-0367.
    PubMed    
    
    
    
61. PIERCE CW
    Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202101-0227.
    PubMed    
    
    
    
62. LE ROUX SP, Upton C, Vanker N, Dooley KE, et al
    Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
    Am J Respir Crit Care Med. 2021;203:635-637.
    PubMed    
    
    
    February 2021
63. ESCALANTE P, Wilson JW
    New Diagnostics to Infer Risk in Tuberculosis: Is the Term Latent Tuberculosis Infection Obsolete?
    Am J Respir Crit Care Med. 2021 Feb 17. doi: 10.1164/rccm.202101-0131.
    PubMed    
    
    
    January 2021
64. MPANDE CAM, Musvosvi M, Rozot V, Mosito B, et al
    Antigen-specific T Cell Activation Distinguishes Between Recent and Remote Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Jan 6. doi: 10.1164/rccm.202007-2686.
    PubMed     Abstract available
    
    
    
65. FRANKE MF, Khan P, Hewison C, Khan U, et al
    Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Am J Respir Crit Care Med. 2021;203:111-119.
    PubMed     Abstract available
    
    
    December 2020
66. HOSODA C, Ishiguro T, Shimizu Y, Kanegane H, et al
    Mycobacterium genavense Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis.
    Am J Respir Crit Care Med. 2020;202:e144-e145.
    PubMed    
    
    
    November 2020
67. KENDALL EA, Shrestha S, Dowdy DW
    The Epidemiological Importance of Subclinical Tuberculosis: A Critical Re-Appraisal.
    Am J Respir Crit Care Med. 2020 Nov 16. doi: 10.1164/rccm.202006-2394.
    PubMed     Abstract available
    
    
    September 2020
68. CHANG KC, Yew WW
    ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
    Am J Respir Crit Care Med. 2020;202:777-778.
    PubMed    
    
    
    
69. SOTGIU G, Battista Migliori G, Menzies D, Mase S, et al
    Reply to Chang and Yew.
    Am J Respir Crit Care Med. 2020;202:778-779.
    PubMed    
    
    
    August 2020
70. DAWRS SN, Kautz M, Chan ED, Honda JR, et al
    Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study.
    Am J Respir Crit Care Med. 2020;202:466-469.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.